A Randomized, Double Blind, Placebo Controlled, Multicenter, Single and Multiple Ascending Dose Study of rhFGF 18 Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Not Requiring Surgery Within One Year.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter, Single and Multiple Ascending Dose Study of rhFGF 18 Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Not Requiring Surgery Within One Year.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 13 Jun 2015 Results of post-hoc analysis presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 06 Dec 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top